3.89
price down icon11.79%   -0.52
after-market After Hours: 3.89
loading
Monte Rosa Therapeutics Inc stock is traded at $3.89, with a volume of 972.89K. It is down -11.79% in the last 24 hours and down -29.91% over the past month.
See More
Previous Close:
$4.41
Open:
$4.17
24h Volume:
972.89K
Relative Volume:
1.37
Market Cap:
$254.96M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-1.7366
EPS:
-2.24
Net Cash Flow:
$-67.76M
1W Performance:
-26.05%
1M Performance:
-29.91%
6M Performance:
-23.87%
1Y Performance:
-43.87%
1-Day Range:
Value
$3.88
$4.24
1-Week Range:
Value
$3.88
$5.27
52-Week Range:
Value
$3.21
$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name
Name
Monte Rosa Therapeutics Inc
Name
Phone
617-949-2643
Name
Address
321 HARRISON AVENUE, BOSTON
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
GLUE's Discussions on Twitter

Compare GLUE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GLUE
Monte Rosa Therapeutics Inc
3.89 254.96M 0 -130.41M -67.76M -2.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 125.55B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 67.78B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 36.24B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.99B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.77B 3.81B -644.79M -669.77M -6.24

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-19-24 Downgrade Wells Fargo Overweight → Equal Weight
Feb-15-24 Initiated Wedbush Outperform
Jan-03-23 Upgrade Wells Fargo Equal Weight → Overweight
Oct-13-22 Initiated UBS Buy
Aug-15-22 Initiated Jefferies Buy
Apr-28-22 Initiated Credit Suisse Neutral
Feb-10-22 Initiated Wells Fargo Equal Weight
Oct-14-21 Initiated SVB Leerink Mkt Perform
View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

pulisher
Mar 29, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Holdings Boosted by Charles Schwab Investment Management Inc. - Defense World

Mar 29, 2025
pulisher
Mar 27, 2025

Chandra Leo Spends US$58k On Monte Rosa Therapeutics Stock - simplywall.st

Mar 27, 2025
pulisher
Mar 26, 2025

Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock - Investing.com Australia

Mar 26, 2025
pulisher
Mar 25, 2025

Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Position Lifted by Bank of New York Mellon Corp - Defense World

Mar 25, 2025
pulisher
Mar 25, 2025

Bank of New York Mellon Corp Buys 3,619 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - ETF Daily News

Mar 25, 2025
pulisher
Mar 24, 2025

Monte Rosa Therapeutics: Exercise Extreme Caution (NASDAQ:GLUE) - Seeking Alpha

Mar 24, 2025
pulisher
Mar 24, 2025

FY2029 Earnings Estimate for GLUE Issued By Wedbush - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Wells Fargo & Company Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 22, 2025
pulisher
Mar 22, 2025

Wedbush Reaffirms Outperform Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Promising Clinical Developments and Strategic Partnerships Drive Buy Rating for Monte Rosa Therapeutics - TipRanks

Mar 22, 2025
pulisher
Mar 22, 2025

Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 - MSN

Mar 22, 2025
pulisher
Mar 21, 2025

Monte Rosa Therapeutics Earnings Call Highlights Progress and Strategic Shifts - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Positive signs for Monte Rosa in early data - The Pharma Letter

Mar 21, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics Reports Strong Q4 2024 Results - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics announces results from MRT-6160, MRT-2359 programs - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics shares surge on strong Q4 revenue beat - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics earnings missed by $0.54, revenue topped estimates - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics shares surge on strong Q4 revenue beat By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics Files $400 Million Mixed Shelf -March 20, 2025 at 10:11 am EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

Earnings call transcript: Monte Rosa Therapeutics Q4 2024 shows strong cash runway - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

MONTE ROSA THERAPEUTICS Earnings Results: $GLUE Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics sees cash runway into 2028 - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics reports Q4 revenue $60.6M, consensus $51.9M - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Updated: Monte Rosa reports first data for molecular glue program licensed to Novartis - Endpoints News

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics Reports Q4 2024 Financial Results - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics Announces Fourth Quarter 2024 - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Monte Rosa's Breakthrough: 90% Target Degradation Success Powers $60M Quarter - StockTitan

Mar 20, 2025
pulisher
Mar 19, 2025

Molecular Glues Market to Register Stunning Growth During the Forecast Period (2025-2034) | DelveInsight - Lelezard

Mar 19, 2025
pulisher
Mar 16, 2025

When (GLUE) Moves Investors should Listen - news.stocktradersdaily.com

Mar 16, 2025
pulisher
Mar 16, 2025

Lexeo Therapeutics (NASDAQ:LXEO) & Monte Rosa Therapeutics (NASDAQ:GLUE) Critical Survey - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

What is Lifesci Capital’s Forecast for GLUE FY2024 Earnings? - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Monte Rosa Therapeutics (NASDAQ:GLUE) Coverage Initiated at Lifesci Capital - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

LifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform Recommendation - Nasdaq

Mar 12, 2025
pulisher
Mar 11, 2025

Monte Rosa Therapeutics to Present Pipeline Update and - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year ... - The Bakersfield Californian

Mar 11, 2025
pulisher
Mar 11, 2025

Monte Rosa Reveals Critical Clinical Data from Two Cancer Drug Trials Plus 2024 Earnings - StockTitan

Mar 11, 2025
pulisher
Mar 09, 2025

Rhumbline Advisers Acquires 9,323 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

Monte Rosa Therapeutics (GLUE) Projected to Post Earnings on Thursday - Defense World

Mar 06, 2025

Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Cap:     |  Volume (24h):